A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Vetsika, Eleni Kyriaki ^a   Koinis, Filippos ^b   Gioulbasani, Marianthi ^a   Aggouraki, Despoina ^a   Koutoulaki, Anna ^a   Skalidaki, Eirini ^a   Mavroudis, Dimitris ^a,b   Georgoulias, Vassilis ^a,b   Kotsakis, Athanasios ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; PLATINUM DERIVATIVE; REACTIVE OXYGEN METABOLITE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SUPPRESSOR CELL; TREATMENT RESPONSE; BLOOD; BONE MARROW CELL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MONOCYTE; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; ANTIGENS, CD14; ANTIGENS, CD15; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; MYELOID CELLS; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; REACTIVE OXYGEN SPECIES; SIALIC ACID BINDING IG-LIKE LECTIN 3; TREATMENT OUTCOME;

EID: 84912081252     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/659294     Document Type: Article

References (39)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. Cancer Journal for Clinicians 2013 63 1 11 30 2-s2.0-84872967522 10.3322/caac.21166
2. Hoang T., Traynor A. M., Schiller J. H., Novel therapies for lung cancer. Surgical Oncology 2002 11 4 229 241 10.1016/S0960-7404(02)00056-7 2-s2.0-0036890088
3. Klebanoff C. A., Acquavella N., Yu Z., Restifo N. P., Therapeutic cancer vaccines: are we there yet? Immunological Reviews 2011 239 1 27 44 2-s2.0-78650574270 10.1111/j.1600-065X.2010.00979.x
4. Thomas A., Hassan R., Immunotherapies for non-small-cell lung cancer and mesothelioma. The Lancet Oncology 2012 13 7 e301 e310 10.1016/S1470-2045(12)70126-2 2-s2.0-84863113633
5. Serafini P., Borrello I., Bronte V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 2006 16 1 53 65 2-s2.0-31344474166 10.1016/j.semcancer.2005.07.005
6. Kronenberg M., Rudensky A., Regulation of immunity by self-reactive T cells. Nature 2005 435 7042 598 604 2-s2.0-20444490383 10.1038/nature03725
7. H-17 cells does require TGF- β ! Nature Immunology 2008 9 6 588 590 10.1038/ni0608-588 2-s2.0-44049108877
8. O'Garra A., Barrat F. J., Castro A. G., Vicari A., Hawrylowicz C., Strategies for use of IL-10 or its antagonists in human disease. Immunological Reviews 2008 223 1 114 131 10.1111/j.1600-065X.2008.00635.x 2-s2.0-47249134619
9. Wrzesinski S. H., Wan Y. Y., Flavell R. A., Transforming growth factor- β and the immune response: implications for anticancer therapy. Clinical Cancer Research 2007 13 18, part 1 5262 5270 10.1158/1078-0432.CCR-07-1157 2-s2.0-34848857434
10. Barber D. L., Wherry E. J., Masopust D., Zhu B., Allison J. P., Sharpe A. H., Freeman G. J., Ahmed R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439 7077 682 687 10.1038/nature04444 2-s2.0-32544459770
11. Korman A. J., Peggs K. S., Allison J. P., Checkpoint blockade in cancer immunotherapy. Advances in Immunology 2006 90 297 339 10.1016/S0065-2776(06)90008-X 2-s2.0-33646794392
12. Sinha P., Chornoguz O., Clements V. K., Artemenko K. A., Zubarev R. A., Ostrand-Rosenberg S., Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 2011 117 20 5381 5390 2-s2.0-79956348160 10.1182/blood-2010-11-321752
13. Yang L., DeBusk L. M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L. M., Carbone D. P., Lin P. C., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004 6 4 409 421 10.1016/j.ccr.2004.08.031 2-s2.0-5444225991
14. Almand B., Clark J. I., Nikitina E., Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. The Journal of Immunology 2001 166 1 678 689 2-s2.0-0035164478 10.4049/jimmunol.166.1.678
15. + T cells. Journal of Clinical Investigation 2006 116 10 2777 2790 2-s2.0-33749425534 10.1172/JCI28828
16. Cheng P., Corzo C. A., Luetteke N., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. The Journal of Experimental Medicine 2008 205 10 2235 2249 10.1084/jem.20080132 2-s2.0-53349099219
17. Serafini P., Mgebroff S., Noonan K., Borrello I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research 2008 68 13 5439 5449 10.1158/0008-5472.CAN-07-6621 2-s2.0-48549085973
18. Li H., Han Y., Guo Q., Zhang M., Cao X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF- β 1. The Journal of Immunology 2009 182 1 240 249 2-s2.0-59849126377 10.4049/jimmunol.182.1.240
19. + T cells. Gastroenterology 2008 135 1 234 243 10.1053/j.gastro.2008.03.020
20. Finke J., Ko J., Rini B., Rayman P., Ireland J., Cohen P., MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. International Immunopharmacology 2011 11 7 856 861 10.1016/j.intimp.2011.01.030 2-s2.0-80054065121
21. Ostrand-Rosenberg S., Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy 2010 59 10 1593 1600 10.1007/s00262-010-0855-8 2-s2.0-77955549860
22. Poschke I., Kiessling R., On the armament and appearances of human myeloid-derived suppressor cells. Clinical Immunology 2012 144 3 250 268 2-s2.0-84864474722 10.1016/j.clim.2012.06.003
23. Liu C. Y., Wang Y. M., Wang C. L., Population alterations of L: -arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14(-)/CD15(+)/CD33(+) myeloid-derived suppressor cells and CD8(+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 2010 136 1 35 45
24. + T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy 2008 57 10 1493 1504 10.1007/s00262-008-0490-9 2-s2.0-48149107380
25. low/- monocytes in prostate cancer. Prostate 2010 70 4 443 455 2-s2.0-76149145359 10.1002/pros.21078
26. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of Clinical Oncology 2007 25 18 2546 2553 10.1200/JCO.2006.08.5829 2-s2.0-34447258415
27. Rodriguez P. C., Ernstoff M. S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A. C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Research 2009 69 4 1553 1560 10.1158/0008-5472.CAN-08-1921 2-s2.0-60549088732
28. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C. R., Nitti D., Bronte V., Zanovello P., IL4R α + myeloid-derived suppressor cell expansion in cancer patients. Journal of Immunology 2009 182 10 6562 6568 10.4049/jimmunol.0803831 2-s2.0-70350133511
29. -/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunology, Immunotherapy 2013 62 9 1439 1451 10.1007/s00262-013-1450-6
30. + monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. The American Journal of Respiratory and Critical Care Medicine 2012 186 10 1025 1036 2-s2.0-84869223841 10.1164/rccm.201204-0636OC
31. Youn J.-I., Nagaraj S., Collazo M., Gabrilovich D. I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology 2008 181 8 5791 5802 10.4049/jimmunol.181.8.5791 2-s2.0-54049134747
32. Movahedi K., Guilliams M., van den Bossche J., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008 111 8 4233 4244 2-s2.0-43249130187 10.1182/blood-2007-07-099226
33. Suzuki E., Kapoor V., Jassar A. S., Kaiser L. R., Albelda S. M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 2005 11 18 6713 6721
34. Kusmartsev S., Gabrilovich D. I., Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology, Immunotherapy 2002 51 6 293 298 10.1007/s00262-002-0280-8 2-s2.0-0036301973
35. Sinha P., Clements V. K., Ostrand-Rosenberg S., Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology 2005 174 2 636 645 10.4049/jimmunol.174.2.636 2-s2.0-11844277698
36. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scandinavian Journal of Immunology 2010 72 6 540 547 10.1111/j.1365-3083.2010.02463.x
37. Gabitass R. F., Annels N. E., Stocken D. D., Pandha H. A., Middleton G. W., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunology, Immunotherapy 2011 60 10 1419 1430 2-s2.0-80054102628 10.1007/s00262-011-1028-0
38. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.-Y., Mendrzyk R., Hilf N., Schoor O., Fritsche J., Mahr A., Maurer D., Vass V., Trautwein C., Lewandrowski P., Flohr C., Pohla H., Stanczak J. J., Bronte V., Mandruzzato S., Biedermann T., Pawelec G., Derhovanessian E., Yamagishi H., Miki T., Hongo F., Takaha N., Hirakawa K., Tanaka H., Stevanovic S., Frisch J., Mayer-Mokler A., Kirner A., Rammensee H.-G., Reinhardt C., Singh-Jasuja H., Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine 2012 18 8 1254 1261 10.1038/nm.2883 2-s2.0-84864662070
39. Gabrilovich D. I., Ostrand-Rosenberg S., Bronte V., Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 2012 12 4 253 268 10.1038/nri3175 2-s2.0-84858785703